EUVIMEDEUVIMED entdecken
Crossref

Clinicopathologic Features and Digital Imaging Analysis of HER2 Protein in Breast Carcinomas With Different HER2 Fluorescence in Situ Hybridization Patterns

Aidan C Li, Scott Hammond, Debra Crosby, Zaibo Li, Anil V Parwani

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2024.10.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Aidan C Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Washington University in St. Louis, St. Louis, MO. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, In Situ Hybridization, Fluorescence, Biomarkers, Tumor. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: HER2-targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer (BC), which represents 15% to 20% of all BC cases. HER2 status is assessed via immunohistochemistry (IHC) and/or in situ hybridization (ISH), dividing BCs into five groups (G1-G5). PATIENTS AND METHODS: In a study of 2,702 primary BC cases, comprising 12.7% G1, 0.2% G2, 2.8% G3, 8.5% G4, and 75.9% G5, we analyzed clinicopathologic features and HER2 protein expression digitally for each ISH group. RESULTS: Notably, G5 cases had a higher proportion of lobular carcinoma (13.9%) compared to other groups. G3 cases showed the highest percentage of grade 3 tumors (56.9%), while G5 cases had the lowest (21.4%). Additionally, G5 cases had the highest rate of estrogen receptor (ER) positivity (84.6%), while G1-HC (high copy number) cases had the lowest (70.4%). Most G1-HC cases were HER2 IHC 3+ (76.1%), while most G5 cases were IHC 0/1+ (75.7%). IHC 2+ was most common in G1-LC (low copy number) and G3 cases (83.8% and 90.7%, respectively), with G4 cases predominantly IHC 2+ (56.3%) and IHC 1+ (30.1%). Discordant HER2 IHC and ISH results were observed in 12 cases (0.4%), including 7 G1-HC (2.3%), 4 G1-LC (10.8%), and 1 G5 case (0.1%). Digital quantification of HER2 IHC levels in all groups except G5 revealed that G1-HC tumors had the highest HER2 protein expression, followed by G3, with G4 showing the lowest. CONCLUSION: These findings offer valuable insights into the clinicopathologic characteristics and future management for different HER2 ISH groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsIn Situ Hybridization, FluorescenceBiomarkers, TumorHumansFemaleMiddle AgedImmunohistochemistryAdultAgedReceptors, EstrogenCarcinoma, Lobular

Stichwörter der Autor:innen

BiomarkerHER2 FISHHER2 IHCHER2 copy numberHER2/CEP17 ratio

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorReceptors, EstrogenERBB2 protein, human

Autor:innen und Institutionen

  • Department of Chemistry, Washington University in St. Louis, St. Louis, MO.
  • Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH.
  • Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH. Electronic address: Zaibo.Li@osumc.edu.
  • Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH. Electronic address: Anil.Parwani@osumc.edu.

Zitieren

APA

Li, A. C., Hammond, S., Crosby, D., Li, Z., & Parwani, A. V. (2025). Clinicopathologic Features and Digital Imaging Analysis of HER2 Protein in Breast Carcinomas With Different HER2 Fluorescence in Situ Hybridization Patterns. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.10.004

Vancouver

Li AC, Hammond S, Crosby D, Li Z, Parwani AV. Clinicopathologic Features and Digital Imaging Analysis of HER2 Protein in Breast Carcinomas With Different HER2 Fluorescence in Situ Hybridization Patterns. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2024.10.004

BibTeX
@article{Li2025,
  author = {Li, Aidan C and Hammond, Scott and Crosby, Debra and Li, Zaibo and Parwani, Anil V},
  title = {Clinicopathologic Features and Digital Imaging Analysis of HER2 Protein in Breast Carcinomas With Different HER2 Fluorescence in Situ Hybridization Patterns},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2024.10.004}
}
Kostenlos starten →